SAGE Therapeutics Inc Q1 2022 Earnings Call Summary - Thomson StreetEvents

SAGE Therapeutics Inc Q1 2022 Earnings Call Summary

SAGE Therapeutics Inc Q1 2022 Earnings Call Summary - Thomson StreetEvents
SAGE Therapeutics Inc Q1 2022 Earnings Call Summary
Published May 03, 2022
20 pages (12100 words) — Published May 03, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of SAGE.OQ earnings conference call or presentation 3-May-22 12:00pm GMT

  
Brief Excerpt:

...A. Highlights: 2022 is off to strong start. 1. Laid groundwork for a year of execution as Co. makes progress on goals to become leader in brain health and top-tier biopharmaceutical Co. a. b. Effort comes at pivotal time as Co. is amid ongoing brain health pandemic, triggering substantial societal and lifestyle disruptions across communities. c. Severity and prevalence of symptoms requires all to strengthen response. 2. Marking mental health awareness month observed in US since May 1949, Co. recommitted to mission of pioneering solutions to deliver life changing brain health medicines. Mental health awareness month provides important reminder of great unmet need in this area. a. b. It's never been more important to prioritize mental health as an essential component to overall health and well being. 3. Importance in need for novel therapies for people living with MDD and PPD, disorders where advancement lagged other critical disease areas. With little innovation in last 60 years, profile...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
SAGE Therapeutics Inc
Ticker
SAGE.OQ
Time
12:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Tiffany Sun - JPMorgan Chase & Co, Research Division - Analyst : This is Tiffany on for Cory. Just one to add on 718. Can you just talk about the trial design differences in the recently initiated Phase II Parkinson's study versus the prior PARADIGM study? And what are you kind of hoping to see with this? And also any sense of cadence for updates?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Given the time you have to complete the submission, could you share any latest thoughts you have on how you might be able to target MDD with elevated anxiety as a use case to include in the label?

Table Of Contents

SAGE Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript – 2022-06-13 – US$ 54.00 – Edited Transcript of SAGE.OQ presentation 13-Jun-22 10:20pm GMT

SAGE Therapeutics Inc SKYLARK Study Topline Data Call Summary – 2022-06-01 – US$ 54.00 – Edited Brief of SAGE.OQ conference call or presentation 1-Jun-22 12:00pm GMT

SAGE Therapeutics Inc SKYLARK Study Topline Data Call Transcript – 2022-06-01 – US$ 54.00 – Edited Transcript of SAGE.OQ conference call or presentation 1-Jun-22 12:00pm GMT

SAGE Therapeutics Inc at Bank of America Healthcare Conference Transcript – 2022-05-11 – US$ 54.00 – Edited Transcript of SAGE.OQ presentation 11-May-22 3:00pm GMT

SAGE Therapeutics Inc Q1 2022 Earnings Call Transcript – 2022-05-03 – US$ 54.00 – Edited Transcript of SAGE.OQ earnings conference call or presentation 3-May-22 12:00pm GMT

SAGE Therapeutics Inc at Stifel CNS Days (Virtual) Transcript – 2022-03-29 – US$ 54.00 – Edited Transcript of SAGE.OQ presentation 29-Mar-22 8:00pm GMT

SAGE Therapeutics Inc at Cowen Health Care Conference (Virtual) Transcript – 2022-03-07 – US$ 54.00 – Edited Transcript of SAGE.OQ presentation 7-Mar-22 3:30pm GMT

SAGE Therapeutics Inc Q4 2021 Earnings Call Summary – 2022-02-24 – US$ 54.00 – Edited Brief of SAGE.OQ earnings conference call or presentation 24-Feb-22 1:00pm GMT

SAGE Therapeutics Inc Q4 2021 Earnings Call Transcript – 2022-02-24 – US$ 54.00 – Edited Transcript of SAGE.OQ earnings conference call or presentation 24-Feb-22 1:00pm GMT

SAGE Therapeutics Inc CORAL Study Topline Results Conference Call Summary – 2022-02-16 – US$ 54.00 – Edited Brief of SAGE.OQ conference call or presentation 16-Feb-22 1:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "SAGE Therapeutics Inc Q1 2022 Earnings Call Summary" May 03, 2022. Alacra Store. May 02, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2022-SAGE-Therapeutics-Inc-Earnings-Call-B15182675>
  
APA:
Thomson StreetEvents. (2022). SAGE Therapeutics Inc Q1 2022 Earnings Call Summary May 03, 2022. New York, NY: Alacra Store. Retrieved May 02, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2022-SAGE-Therapeutics-Inc-Earnings-Call-B15182675>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.